Eisai, University of Gothenburg deal

Eisai’s Morphotek Inc. subsidiary partnered with the Targeted Alpha Therapy (TAT) Group at the university to research and develop Eisai’s farletuzumab for radio-immunotherapy in ovarian cancer. The h...